Notch Signaling Inhibition by LY411575 Attenuates Osteoblast Differentiation and Decreased Ectopic Bone Formation Capacity of Human Skeletal (Mesenchymal) Stem Cells by Nihal AlMuraikhi (6002234)

“…We identified γ-secretase inhibitor (LY411575) as a potent regulator of osteoblastic differentiation of hBMSC that may be useful as a therapeutic option for treating conditions associated with ectopic bone formation.…”

Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications by Gulab Sher (12984698)

“…<p dir="ltr">The global burden of breast cancer (BC) is increasing significantly. This trend is caused by several factors such as late diagnosis, limited treatment options for certain BC subtypes, drug resistance which all lead to poor clinical outcomes. …”

Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions by Sama Ayoub (15430987)

“…Since therapeutic options are minimal, a deeper understanding of the pathophysiology is essential for improved diagnosis and treatments. …”

HbA1c over 8.5% is not predictive of increased infection rate following penile prosthesis implant surgery in diabetic patients with erectile dysfunction by Raidh Talib (14779198)

“…<p dir="ltr">Diabetes mellitus is associated with increased risk of erectile dysfunction. Penile prosthesis implantation is an efficient therapeutic option for erectile dysfunction, but not without risk, as infection remains a prominent concern. …”

Efficacy And Safety of Cannabidiol on Juvenile Diabetes Outcomes in Male Rats by Awkar, Nai

Get full text
Get full text
Get full text

Arginine Deprivation in AML Cells Induces Ferroptosis, a Type of Autophagy-Mediated Cell Death by Tohme, Sara

Get full text
Get full text
Get full text

Bone-targeted therapies in metastatic castration-resistant prostate cancer by El-Amm, Joelle

“…Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. Emerging therapeutics in mCRPC has resulted in great strides in preventing one of the most significant sources of complications of bone metastases.…”
Get full text
Get full text
Get full text
Get full text

1787 evaluation of transperineal prostatic administration of a PSA-activasted protoxin (PRX302) in men with luts secondary to BPH by Elhilali, Mostafa

“…PRX302 could offer an interesting therapeutic option for patients with LUTS 2ry to BPH.…”
Get full text
Get full text
Get full text
Get full text

Comprehensive Transcriptome and Pathway Analyses Revealed Central Role for Fascin in Promoting Triple-Negative Breast Cancer Progression by Rayanah Barnawi (8737584)

“…However, cancer-related death remains high especially in triple-negative breast cancer (TNBC) due limited therapeutic options. Development of targeted therapies for TNBC requires better understanding of biology and signaling networks that promote disease progression. …”

Sanguinarine mediated apoptosis in Non-Small Cell Lung Cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway by Kirti.S. Prabhu (17191231)

“…<p dir="ltr">Effective treatment of lung cancer remains a significant clinical challenge due to its multidrug resistance and side effects of the current treatment options. The high mortality associated with this malignancy indicates the need for new therapeutic interventions with fewer side effects. …”

Pharmacophore-Model-Based Virtual-Screening Approaches Identified Novel Natural Molecular Candidates for Treating Human Neuroblastoma by F A Dain Md Opo (14123109)

“…<div><p>The mortality of cancer patients with neuroblastoma is increasing due to the limited availability of specific treatment options. …”

Inhibition of T-cell activity in alopecia areata: recent developments and new directions by Thierry Passeron (6995899)

“…Several other treatments are used off-label with limited efficacy and/or suboptimal safety and tolerability. With an increased understanding of the T-cell–mediated autoimmune and inflammatory pathogenesis of AA, additional therapeutic pathways beyond JAK inhibition are currently under investigation for the development of AA therapies. …”

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer by Said Dermime (79420)

“…<p dir="ltr">Immune checkpoint blockade (ICB) has been approved as first- or second-line therapy options in a broadening range of metastatic cancer and is increasingly explored in the treatment of early stage tumors. …”

A possible culprit for refractory angina by Nature Research (16552612)

“…The new findings suggest that elevated lipoprotein(a) levels may play a causative role in the condition, and that reducing levels of this lipoprotein could be a viable therapeutic option for the patients.</p><p>Angina occurs when cholesterol plaques are deposited in the coronary arteries, causing a shortage in blood supply to the heart itself. …”

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy by Nassiba Taib (14557385)

“…In addition, induction of NY-ESO-1 may represent an immuno-therapeutic option in metastatic CRC patients. Finally, the combination of DAC and anti-PD-1/anti-PD-L1 antibodies treatment should represent a potential therapeutic intervention for this group of patients.…”

Salvage surgery for esophageal cancer by Cohen, Charlotte

“…Salvage surgery (SALV) is considered the best treatment option in case of persistent or recurrent disease for operable patients, but SALV has been associated with increased morbidity and mortality. …”
Get full text
Get full text
Get full text
Get full text

Hedgehog Signaling Inhibition by Smoothened Antagonist BMS-833923 Reduces Osteoblast Differentiation and Ectopic Bone Formation of Human Skeletal (Mesenchymal) Stem Cells by Nihal AlMuraikhi (6002234)

“…We identified SMO/Hedgehog antagonist (BMS-833923) as a powerful inhibitor of osteoblastic differentiation of hMSC that may be useful as a therapeutic option for treating conditions associated with high heterotopic bone formation and mineralization.…”

Cardiovascular Efficacy and Safety of Finerenone: A Meta‐Analysis of Randomized Controlled Trials by Mushood Ahmed (19231379)

“…<h3>Background</h3><p dir="ltr">Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has emerged as a novel therapeutic option for the management of patients with diabetes, chronic kidney disease, or heart failure. …”